160 likes | 271 Vues
The SILEN-C1 trial demonstrates that treatment with the second-generation HCV protease inhibitor BI 201335 results in high and consistent sustained virologic response (SVR) rates among treatment-naïve patients with HCV genotype 1. This research analyzes various baseline factors, including age, gender, ALT and GGT levels, HCV RNA, subtype, and IL28B, to identify predictors of SVR. The findings highlight the effectiveness of BI 201335 and its potential to improve outcomes for patients with HCV genotype 1.
E N D
Treatment with the second-generation HCV protease inhibitor BI 201335 results in high and consistent SVR rates:Results from SILEN-C1 in HCV genotype-1 treatment-naïve patients across different baseline factors